Stock News

The applications follow a Phase 3 trial showing 27 per cent fewer painful crises versus placebo, with regulatory action expected in 2027.

A one-time gain is expected to exceed fourth-quarter operating expenses, while full-year guidance still calls for a loss.

Convertible-note principal stood at US$486.5 million, with about 16,116 bitcoin pledged as the company evaluates operating businesses.

The lender becomes its largest shareholder with 9.9 per cent, while the Okanjande stream expands to cover all future production.

Both headline growth rates compare with Q2, while Columbiana billing is expected to start in January 2027.

September liquidity of US$145.4 million is forecast to last into late 2028, beyond the expected ReVeRA-301 trial readout.

The existing 165 million USDT balance remains due in 2027, while eligible positive net derivatives value can count toward collateral requirements.

The explorer will reassess working capital needs and financing alternatives after dropping its October offering.

The silver producer narrowed its net loss to US$5.6 million, while quarter-end cash fell to US$63.3 million.

Twelve participants stopped intravenous glucose, while final statistics are due in December and a US$100M offering is expected to close Nov. 16.

The Alberta proposal carried an estimated US$30M to US$35M cost, while token revaluation drove the quarterly profit.

The hard-metal division nearly doubled revenue, while favourable timing between raw-material pricing and costs helped lift profitability.

Natural graphite capacity could grow 20 per cent as China retains its dominance and Western tungsten projects face commissioning milestones.

Selective sampling identified a new skarn target south of Lamb Mountain, but GoldHaven has not dated follow-up work.

Omineca would retain a 50 per cent carried interest and receive half the recovered gold at a base cost of C$1,000 an ounce.

The 26-patient trial supports a priority review request, but the Nov. 12 release gives no FDA acceptance date or decision deadline.

EsoGuard test volume reached a monthly record in October, while quarterly operating expenses were US$13.5 million.

The partners will combine CPUs, GPUs and adaptive computing, with more details due at Chicago's SC26 conference on Nov. 15 to 20.

True widths are estimated at 70 to 90 per cent of drilled lengths, with assays from 54 holes still pending.

International medical sales supplied 59 per cent of quarterly revenue, while gross margin and adjusted EBITDA declined sequentially.

The orexin-targeting tablet is now available through a specialty pharmacy, following the FDA's Aug. 5 approval.

The proposed 1 GW facility accounts for most of the announced budget, but ReNew has disclosed neither financing terms nor a delivery date.

The system supports 150 mm and 200 mm wafers, but the company disclosed no purchase price, delivery date or output target.

Operating cash flow rose 115 per cent to US$48 million as Aya raised the floor of its Zgounder silver production forecast.

Most consolidated cash sits at WhiteFiber, while pledged ether supports borrowing and new project financing remains subject to funding conditions.

The company says the FDA will not hold an advisory panel as it prepares for a Feb. 12 decision on its Stargardt disease application.

Reliquias targets throughput of 800 tonnes a day in the second half of 2027, with its next operational update expected in January.

The provider's final review confirms the removal, while its public notice gives no dollar estimate of passive-fund selling.

The quantum-computer developer held US$497.1 million in cash and investments as it targeted a larger system for mid-2028.

Concentrate from Burswood will go to Curtin's C4P facility, with samples intended for assessment before potential refining-partner evaluation.

Only US$1.5 million is upfront; the balance depends on warrants, with first U.S. patient dosing targeted for the second quarter of 2027.

New breast and lung cancer applications aim to inform therapy choices when conventional mutation markers leave gaps.

The STOXX Europe 600 advanced as AI demand optimism met higher infrastructure spending, with Nvidia results scheduled for Nov. 17.

Excellon would retain 19.9 per cent of the German explorer while shareholders keep their proportionate interest in its Peru-focused business.